Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Seeks Chronic Hives Indication for Xolair
June 20, 2016
- Aspen Japan Looks to Expand Biz through Essential Drugs, AGs: President
June 20, 2016
- Jardiance Reduces Kidney Disease Risks Too, by 39%
June 17, 2016
- Eisai to Book 9.2 Billion Yen Gain from EA Pharma Share Acquisition
June 17, 2016
- AnGes MG to License Oral CIN Therapeutic Vaccine to Morishita Jintan
June 17, 2016
- PeptiDream’s Macrocyclic Compound Advances to Clinical Stage
June 16, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
- Selexipag Reaches European Soil, Now Available in Germany: Nippon Shinyaku
June 16, 2016
- Novartis Japan to Revamp Ophthalmology Drug Biz amid Global Drive
June 16, 2016
- Roche to Top Global Drug Maker Ranking in 2020, Consulting Firm Predicts
June 16, 2016
- Merck Serono Can Catch Up with Rivals in Immuno-Oncology Space: Japan Oncology Head
June 16, 2016
- Eisai’s Anti-Fractalkine Antibody Suggests Safety in RA
June 15, 2016
- Sawai to Make 700 Factory Contractors Permanent Employees
June 15, 2016
- SymBio Kicks Off Japan PIII for Patient-Controlled Pain Management Drug
June 15, 2016
- PDUFA Date Set for Jan. 31, 2017 for Daiichi Sankyo’s Nausea Drug
June 15, 2016
- Otsuka, Acucela End Partnership on AMD Drug after Trial Data Disappoint
June 15, 2016
- Ethical Drug Sales Up 8.1% in April: Crecon Report
June 14, 2016
- No Higher Mortality Risk Including CV Death Observed with Alogliptin against Placebo: Takeda
June 14, 2016
- Dave Fredrickson Tapped as Next Chief of AstraZeneca Japan
June 13, 2016
- Takeda Looks to Join Top 10 List in Global Oncology Space in 2025
June 10, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…